ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 33 of 62 for:    dry mouth | NIH

Randomized Amifostine For SCCHN

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00095927
Recruitment Status : Completed
First Posted : November 9, 2004
Last Update Posted : January 4, 2017
Sponsor:
Collaborators:
National Cancer Institute (NCI)
MedImmune LLC
AstraZeneca
Information provided by (Responsible Party):
Robert I. Haddad, MD, Dana-Farber Cancer Institute

November 9, 2004
November 9, 2004
January 4, 2017
May 2003
June 2007   (Final data collection date for primary outcome measure)
  • Rate of local/regional control (LRC) 1 year after beginning treatment [ Time Frame: One year after beginning of treatment ]
  • Proportion of patients with grade 2 or 3 chronic xerostomia at 3, 6 months [ Time Frame: 3, 6 Months ]
  • Proportion of patients with grade 3 and 4 mucositis as assessed by RTOG criteria once weekly during and after completion of radiotherapy [ Time Frame: End of Radiotherapy ]
  • Median duration of dependence on percutaneous endoscopic gastrectomy (PEG) for adequate nutrition at 8, 12, 24, and 52 weeks after completion of study treatment [ Time Frame: 8,12, 24 and 52 weeks ]
Not Provided
Complete list of historical versions of study NCT00095927 on ClinicalTrials.gov Archive Site
  • Duration of grade 3 and 4 mucositis once weekly during treatment and at 8, 12, 24, and 52 weeks after completion of study treatment [ Time Frame: 8, 12, 24, and 52 weeks ]
  • Proportion of patients with PEG dependency [ Time Frame: 3, 6, and 12 months after completion of study treatment ]
  • Time to disease progression [ Time Frame: baseline to disease progression ]
    Kaplan and Meier
  • Quality of life as assessed by Functional Assessment of Cancer Therapy for Head and Neck Cancer (FACT-H&N) Survey [ Time Frame: baseline, 8, 12, 24, and 52 weeks after completion of study treatment ]
  • LRC and overall survival at 2 years after completion of study treatment [ Time Frame: 2 Years after completion of study treatment ]
  • Swallowing function [ Time Frame: 2 years Post treatment ]
Not Provided
Not Provided
Not Provided
 
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.

Amifostine is a drug that is used to treat moderate to severe xerostomia (dry mouth) for those who receive radiation therapy for head and neck cancer. It was approved by the FDA for use intravenously. This study plans to examine the effects of xerostomia when Amifostine is used subcutaneously (by injection). Amifostine has been seen to be effective when used to combat the effects of dry mouth, but also has some side effects which are listed later in this consent form.

The purpose of this study is to examine the effectiveness of twice a day radiation therapy given with chemotherapy consisting of carboplatin and paclitaxel (Taxo 1). This study will examine the effectiveness of adding Amifostine in the hopes of reducing the side effects of radiation.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Chemotherapeutic Agent Toxicity
  • Head and Neck Cancer
  • Mucositis
  • Radiation Toxicity
  • Xerostomia
  • Drug: Amifostine
    Given subcutaneously
    Other Name: Ethyo
  • Drug: Carboplatin
    Given IV
    Other Name: Paraplatin
  • Drug: Paclitaxel
    Given IV
    Other Names:
    • Taxol
    • Onxal
  • Radiation: radiation
    Given once daily for 4 weeks and then twice daily for 2 weeks.
  • Active Comparator: Arm A Amifostine

    Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;

    • 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).
    • Subcutaneous daily amifostine at a dose of 500 mg
    Interventions:
    • Drug: Amifostine
    • Drug: Carboplatin
    • Drug: Paclitaxel
    • Radiation: radiation
  • Experimental: Arm B No-Amifostine

    Patients with newly diagnosed, locally advanced stage ill or IV SCCHN

    - 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).

    Interventions:
    • Drug: Carboplatin
    • Drug: Paclitaxel
    • Radiation: radiation
Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 1;115(19):4514-23. doi: 10.1002/cncr.24525.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
Not Provided
June 2008
June 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Histologically or cytologically proven squamous cell carcinoma of the head and neck. Biopsy is preferred unless medically contraindicated.
  • Primary tumor sites eligible: oral cavity, oropharynx, hypopharynx or larynx. Tumors of the nasal and paranasal cavities will also be included. Unknown primary SCC in the neck will also be eligible.
  • Stage 2, 3 or 4 disease without evidence of distant metastases verified by chest X-Ray, abdominal ultrasound or CT (in case of liver function test abnormalities); bone scan in case of local symptoms.
  • At least one uni- or bidimensionally measurable lesion at the start of all therapy (induction therapy ag well as chemoradiation).
  • No previous head and neck radiotherapy and no previous curative surgery for SCCHN (other than biopsy) are allowed at time of study entry.
  • Age ≥ 18 years.
  • WHO performance status of 0 or 1 (section 13, Appendix I)
  • No active alcohol addiction (as assessed by medical caregiver).
  • Life expectancy ≥ 12 weeks.
  • Signed informed consent prior to beginning protocol specific procedures.
  • Adequate bone marrow, hepatic and renal functions as evidenced by the following:

    • Hematology:

      • neutrophil count ≥ 2.0 x 10 9/1.
      • platelet count ≥ 100 x 10 9/1.
      • hemoglobin ≥ 10 g/dl.
    • Hepatic function:

      • total bilinthin WNL.
      • ASAT (SGOT) and ALAT (SGPT) ≤ 2.5 x 1JLN.
      • alkaline phosphatase ≤ 5 x ULN.
      • patients with ASAT or ALAT > 1.5 x ULN associated with alkaline phosphatase > 2.5
      • x ULN are not eligible for the study.
    • Renal function: the creatinine clearance ≥ 60 ml/min (actual or calculated by the Cockcroft-Gault method as follows:

      • Weight(kg) x (140 — age)/K x serum creatinine
      • serum creatinine in mg/dL

        • K: 72 in man
        • K: 85 in woman
      • serum creatinine in µmon/L

        • K: 0.814 in man
        • K: 0.96 in woman
  • Patients must be available for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centers
  • Previous chemotherapy is permitted, provided that it is in induction form before starting radiation therapy and that it is being used to treat head and neck cancers.

Exclusion Criteria:

  • Pregnant or lactating women, or women of childbearing potential not using adequate contraception.
  • Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 3 years.
  • Symptomatic peripheral neuropathy ≥ grade 2 by NCIC-CTG criteria.
  • Other serious illnesses or medical conditions including but not limited to:

    • Unstable cardiac disease despite treatment, myocardial infarction within 6 months prior to study entry
    • History of significant neurologic or psychiatric disorders including dementia or seizures.
    • Active uncontrolled infection.
    • Active peptic ulcer.
    • Hypercalcemia.
    • Chronic obstructive pulmonary disease requiring hospitalization during the year preceding study entry.
  • Patients requiring intravenous alimentation.
  • Patients who experienced a weight loss of more than 20% of their body weight in the 3 months preceding study entry (unless purposeful)
  • Concurrent treatment with any other anticancer therapy.
  • Participation in an investigational trial within 30 days of study entry.
  • Previous treatment with any biologic therapy is not permitted.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00095927
03018
P30CA006516 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Plan to Share IPD: No
Robert I. Haddad, MD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • National Cancer Institute (NCI)
  • MedImmune LLC
  • AstraZeneca
Principal Investigator: Robert I. Haddad, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP